Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of News

<< 2012 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2014 >>

27 November 2013: UCLB funded research wins prize in Roche Pharma Research & Early Development Oncology Awards

Vineeta Tripathi from the UCL Institute of Ophthalmology has won third prize in the first Roche Pharma Research & Early Development (pRED) Oncology Awards in the field of ‘Novel Highly tumour-selective Membrane Targets for Antibody-based Cancer Therapy’, for work originally co-funded by UCLB. More...

22 November 2013: How to respond when the grand vision becomes a cold reality

New ventures are started for many reasons, with one of the most common routes beginning with someone doing a job they like in a big company and thinking they want to do it for themselves, but where do they go from there, asks Timothy Barnes, Director of UCL Enterprise Operations and UCL Advances. More...

1 November 2013: UCL PhD student awarded £80k Fellowship for ground-breaking solar research

UCL PhD student Patrick Cottam has been awarded an Industrial Fellowship by the Royal Commission for the Exhibition of 1851, worth £80,000. More...

<< 2012 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2014 >>